158 related articles for article (PubMed ID: 37541133)
1. Plasma neurofilament light-chain and phosphorylated tau as biomarkers of disease severity in Huntington's disease: Korean cohort data.
Hwang YS; Oh E; Kim M; Lee CY; Kim HS; Chung SJ; Sung YH; Yoon WT; Cho JH; Lee JH; Kim HJ; Chang HJ; Jeon B; Woo KA; Ko SB; Kwon KY; Moon J; Shin C; Kim YE; Lee JY
J Neurol Sci; 2023 Sep; 452():120744. PubMed ID: 37541133
[TBL] [Abstract][Full Text] [Related]
2. Tau or neurofilament light-Which is the more suitable biomarker for Huntington's disease?
Niemelä V; Landtblom AM; Blennow K; Sundblom J
PLoS One; 2017; 12(2):e0172762. PubMed ID: 28241046
[TBL] [Abstract][Full Text] [Related]
3. Associations between prognostic index scores and plasma neurofilament light in Huntington's disease.
Parkin GM; Corey-Bloom J; Long JD; Snell C; Smith H; Thomas EA
Parkinsonism Relat Disord; 2022 Apr; 97():25-28. PubMed ID: 35276585
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Blood Glial Fibrillary Acidic Protein as a Potential Marker in Huntington's Disease.
You H; Wu T; Du G; Huang Y; Zeng Y; Lin L; Chen D; Wu C; Li X; Burgunder JM; Pei Z
Front Neurol; 2021; 12():779890. PubMed ID: 34867769
[No Abstract] [Full Text] [Related]
5. Plasma neurofilament light in Huntington's disease: A marker for disease onset, but not symptom progression.
Parkin GM; Corey-Bloom J; Snell C; Castleton J; Thomas EA
Parkinsonism Relat Disord; 2021 Jun; 87():32-38. PubMed ID: 33940564
[TBL] [Abstract][Full Text] [Related]
6. Plasma NfL as a prognostic biomarker for enriching HD-ISS stage 1 categorisation: a cross-sectional study.
Parkin GM; Thomas EA; Corey-Bloom J
EBioMedicine; 2023 Jul; 93():104646. PubMed ID: 37315450
[TBL] [Abstract][Full Text] [Related]
7. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis.
Byrne LM; Rodrigues FB; Blennow K; Durr A; Leavitt BR; Roos RAC; Scahill RI; Tabrizi SJ; Zetterberg H; Langbehn D; Wild EJ
Lancet Neurol; 2017 Aug; 16(8):601-609. PubMed ID: 28601473
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease.
Rodrigues FB; Byrne L; McColgan P; Robertson N; Tabrizi SJ; Leavitt BR; Zetterberg H; Wild EJ
J Neurochem; 2016 Oct; 139(1):22-5. PubMed ID: 27344050
[TBL] [Abstract][Full Text] [Related]
9. Mapping neurodegeneration across the Huntington's disease spectrum: a five-year longitudinal analysis of plasma neurofilament light.
Parkin GM; Thomas EA; Corey-Bloom J
EBioMedicine; 2024 Jun; 104():105173. PubMed ID: 38815362
[TBL] [Abstract][Full Text] [Related]
10. Neurofilament Light Protein as a Potential Blood Biomarker for Huntington's Disease in Children.
Byrne LM; Schultz JL; Rodrigues FB; van der Plas E; Langbehn D; Nopoulos PC; Wild EJ
Mov Disord; 2022 Jul; 37(7):1526-1531. PubMed ID: 35437792
[TBL] [Abstract][Full Text] [Related]
11. Application Value of Serum Neurofilament Light Protein for Disease Staging in Huntington's Disease.
Li XY; Bao YF; Xie JJ; Gao B; Qian SX; Dong Y; Wu ZY
Mov Disord; 2023 Jul; 38(7):1307-1315. PubMed ID: 37148558
[TBL] [Abstract][Full Text] [Related]
12. Plasma neurofilament light as a promising biomarker in neuronal intranuclear inclusion disease.
Liu M; Zhu Y; Yuan Y; Wang Y; Liu X; Li L; Gao Y; Yan H; Liu R; Cheng L; Yuan J; Wang Q; Li S; Liu Y; Wang Y; Shi C; Xu Y; Yang J
J Neurol; 2024 Apr; 271(4):2042-2052. PubMed ID: 38189920
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease.
Byrne LM; Rodrigues FB; Johnson EB; Wijeratne PA; De Vita E; Alexander DC; Palermo G; Czech C; Schobel S; Scahill RI; Heslegrave A; Zetterberg H; Wild EJ
Sci Transl Med; 2018 Sep; 10(458):. PubMed ID: 30209243
[TBL] [Abstract][Full Text] [Related]
14. Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease.
Reilmann R; Bohlen S; Klopstock T; Bender A; Weindl A; Saemann P; Auer DP; Ringelstein EB; Lange HW
Mov Disord; 2010 Oct; 25(13):2195-202. PubMed ID: 20645403
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington's disease.
Niemelä V; Burman J; Blennow K; Zetterberg H; Larsson A; Sundblom J
PLoS One; 2018; 13(2):e0193492. PubMed ID: 29474427
[TBL] [Abstract][Full Text] [Related]
16. Early grey matter changes in structural covariance networks in Huntington's disease.
Coppen EM; van der Grond J; Hafkemeijer A; Rombouts SA; Roos RA
Neuroimage Clin; 2016; 12():806-814. PubMed ID: 27830113
[TBL] [Abstract][Full Text] [Related]
17. Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington's disease R6/2 mice.
Soylu-Kucharz R; Sandelius Å; Sjögren M; Blennow K; Wild EJ; Zetterberg H; Björkqvist M
Sci Rep; 2017 Oct; 7(1):14114. PubMed ID: 29074982
[TBL] [Abstract][Full Text] [Related]
18. Translatable plasma and CSF biomarkers for use in mouse models of Huntington's disease.
Bondulich MK; Phillips J; Cañibano-Pico M; Nita IM; Byrne LM; Wild EJ; Bates GP
Brain Commun; 2024; 6(1):fcae030. PubMed ID: 38370446
[TBL] [Abstract][Full Text] [Related]
19. Cortical microstructural correlates of plasma neurofilament light chain in Huntington's disease.
Sampedro F; Pérez-Pérez J; Martínez-Horta S; Pérez-González R; Horta-Barba A; Campolongo A; Izquierdo C; Pagonabarraga J; Gómez-Ansón B; Kulisevsky J
Parkinsonism Relat Disord; 2021 Apr; 85():91-94. PubMed ID: 33770670
[TBL] [Abstract][Full Text] [Related]
20. Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment.
Giacomucci G; Mazzeo S; Bagnoli S; Ingannato A; Leccese D; Berti V; Padiglioni S; Galdo G; Ferrari C; Sorbi S; Bessi V; Nacmias B
J Neurol; 2022 Aug; 269(8):4270-4280. PubMed ID: 35288777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
